Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The results will support regulatory submissions to the FDA and EMA.
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix. Read more here.
GSK shingles vaccine now available in Malaysia
A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR, Malaysia, Sept. /PRNewswire/ -- GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine,
GSK Shingles Vaccine in Malaysia: Here’s What You Need to Know
GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side effects, for whom and where to get it.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial showed that co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ produced a non-inferior immune response and was well tolerated.
GSK Ends Development of Herpes Vaccine Candidate After Disappointing Trial Results
A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
Joplin Globe
2d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
About the NCT05966090 trial The co-administration study is a phase 3, open-label, multi-country study to assess non-inferiority of immune responses in co-administration of
GSK
’s RSV and Recombinant ...
bernama
3d
Shingles May Cause Long-Term Pain In Older People – Expert
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
dermatologyadvisor
7d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50 Years or Older
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Secret Service admits failure
Kentucky judge fatally shot
$230 million crypto theft
Russia threatens retaliation
Boy kills bear, saves father
Families lose appeal
Secret Service probing post
Body found in SUV
Three Mile Island to reopen
FCC chair denies Trump call
1st rabies outbreak in seals
Hiker injured in bear attack
Baby powder recalled
Hold campaign event in MI
Recalling 449K+ vehicles
Top Hezbollah leader killed?
MS sheriff's office probe
PGA welcomes LIV players
Sues pharmacy middlemen
144K+ Mavericks recalled
Collapse hazard recall
Vows to remain in race
Raises settlement offer
Stein's ballot bid rejected
In-person voting begins
Disney to stop using Slack
Brazil threatens daily fines
$3B for battery projects
FTC on privacy controls
To visit US next week
Overdose deaths drop in US
Related topics
RSV
GlaxoSmithKline
Rous sarcoma virus
Feedback